Abstract | BACKGROUND: METHODS: RESULTS: Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P= 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg(2)/dL(2) difference, P= 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20% to 24% more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95% CI 1.28-4.37, P= 0.0058], and 15% to 20% more likely to attain goal Ca x P (OR 2.16, 95% CI 1.20-3.86, P= 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). CONCLUSION:
|
Authors | Wajeh Y Qunibi, Robert E Hootkins, Laveta L McDowell, Micah S Meyer, Matthias Simon, Rodolfo O Garza, Russell W Pelham, Mark V B Cleveland, Larry R Muenz, David Y He, Charles R Nolan |
Journal | Kidney international
(Kidney Int)
Vol. 65
Issue 5
Pg. 1914-26
(May 2004)
ISSN: 0085-2538 [Print] United States |
PMID | 15086935
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetates
- Bicarbonates
- Calcium Compounds
- Epoxy Compounds
- Parathyroid Hormone
- Polyamines
- Polyethylenes
- Phosphorus
- Sevelamer
- Calcium
- calcium acetate
|
Topics |
- Acetates
(therapeutic use)
- Adult
- Aged
- Bicarbonates
(blood)
- Calcium
(blood)
- Calcium Compounds
- Double-Blind Method
- Epoxy Compounds
(therapeutic use)
- Female
- Humans
- Hypercalcemia
(blood)
- Hypocalcemia
(blood)
- Male
- Middle Aged
- Parathyroid Hormone
(blood)
- Phosphorus
(blood)
- Polyamines
(therapeutic use)
- Polyethylenes
(therapeutic use)
- Prospective Studies
- Renal Dialysis
- Sevelamer
|